There are currently 441 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors
NCT06260332
Recruiting
This clinical trial tests whether increased activity throughout the day can improve the chronic pain and associated symptoms that breast cancer survivors may experience after surgery. Staying active is a key factor of one's physical, mental, and social health and well-being. Moving more could also reduce pain and associated stress, anxiety, or depression. Using a fitness tracker may help patients to move around more, whether or not they choose to exercise. Information gathered from this study ma... Read More
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
02/06/2024
Locations: University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico
Conditions: Breast Cancer
Register for Updates
Strength After Breast Cancer
NCT06052488
Recruiting
The goal of this study is to explore whether a group exercise program called Strength After Breast Cancer can be delivered in an outpatient physical therapy clinic to improve physical function among women after treatment for breast cancer. The main questions this study aims to answer are: * Can the Strength After Breast Cancer program and the associated outcome battery be successfully delivered in an outpatient physical therapy clinic at Massachusetts General Hospital and do participants find... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: MGH Institute of Health Professions, Boston, Massachusetts
Conditions: Breast Cancer
Register for Updates
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
NCT05654532
Recruiting
This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: * Identify the recommended dose of AC699 that can be given safely to participants * Evaluate the safety profile of AC699 * Evaluate the pharmacokinetics of AC699 * Evaluate the effectiveness of AC699
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Site 02, Sarasota, Florida +4 locations
Conditions: Breast Cancer
Register for Updates
Losartan in Prevention of Radiation-Induced Heart Failure
NCT05607017
Recruiting
This study is being done to see if losartan affects the chances of developing radiation-induced heart failure in patients who are receiving radiation therapy as part of standard of care treatment for breast cancer. The interventions involved in this study are: * Losartan * Radiation Therapy (standard of care)
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/11/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Breast Cancer, Myocardial Fibrosis, Radiation-Induced Fibrosis
Register for Updates
Ultrahypofractionation and Normal Tissue Toxicity
NCT05912231
Recruiting
This research is being done to see if proton beam radiation therapy (PBT) results in fewer changes to a participant's heart measured with MRI-imaging than conventional or "photon" radiation therapy (XRT) for participants with non-metastatic left sided breast cancer. The names of the two study groups in this research study are: * Proton Radiation Therapy (PBT) * Conventional or "Photon" Radiation Therapy (XRT)
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/11/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Breast Cancer, Breast Cancer Female, Breast Cancer Stage II, Breast Cancer Stage III, Myocardial Fibrosis
Register for Updates
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
NCT06085742
Recruiting
This is a non-randomized, single arm phase 2 trial of oral CMC based on conversion of doses that would be delivered with conventional metronomic CMF chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2024
Locations: University of Illinois, Chicago, Illinois
Conditions: Breast Cancer
Register for Updates
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
NCT01034033
Recruiting
The purpose of this study is to try to understand the biology of development of breast, ovarian, fallopian tube, peritoneal or endometrial cancer from persons at high genetic risk for these diseases. The influence of environmental factors on cancer development in individuals and families will be studied. The efficacy of treatments for these diseases will be evaluated.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/05/2024
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Breast Cancer, Ovarian Cancer, Gynecologic Cancers, Ovarian/Peritoneal/Fallopian Cancer
Register for Updates
Ultrasound Imaging and Spectroscopy as Early Indicators of Locally-Advanced Breast Cancer Response
NCT04134780
Recruiting
This work explores the possibility of using ultrasound imaging and spectroscopy as a way of monitoring cell death, hence, tumour response to treatment. The hypothesis here is that it can be used as a way of monitoring early response to cancer treatment and predicting which patients continue on in their therapy to have a complete pathological response as a primary endpoint and tumour size decrease as a secondary endpoint. If this work is successful it could be used in the future early on in a can... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/07/2023
Locations: MD Anderson, Houston, Texas +2 locations
Conditions: Breast Cancer
Register for Updates
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
NCT05935384
Recruiting
The purpose of SIBYL is to generate clinical validity data for the ability of a future version of Guardant360 developed by Guardant Health to measure response to systemic therapy in patients with unresectable advanced solid tumors. It is necessary to collect clinical data points and treatment outcomes in order to demonstrate clinical validity for longitudinal monitoring with ctDNA and correlation of ctDNA dynamics with therapeutic response, as evaluated by standard methods, including RECIST 1.1... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/17/2023
Locations: Orchard Healthcare Research Inc., Skokie, Illinois
Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer
Register for Updates
Core Biopsies for Establishing a Breast Tumor Tissue Repository
NCT02250352
Recruiting
This research trial establishes a breast tumor tissue repository from core biopsies. Collecting breast tissue from core biopsies may allow doctors to learn more about the biology of breast cancer and to analyze proteins, genes, and other components of tumor cells. It may also allow doctors to conduct future studies to help understand how breast cancer grows and how it responds to different types of therapy. This will help doctors develop better breast cancer therapies and better tests to help ma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Breast Cancer
Register for Updates
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT05283330
Recruiting
A Phase 1 SAD/MAD dose escalation and expansion study to determine the safety and effectiveness of ²¹²Pb-DOTAM-GRPR1 in subjects with various GRPR-expressing Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: Northwestern University Robert H Lurie Medical Research, Chicago, Illinois +3 locations
Conditions: Cervical Cancer, Prostate Cancer Metastatic, Breast Cancer, Colon Cancer, NSCLC, Cutaneous Melanoma
Register for Updates
Social Risk Factors and Discrimination in Cancer Survivorship
NCT05301114
Recruiting
The objective of the proposed study is to scale social risk factor screening and referral for cancer survivors and to solidify information exchange between clinical and community settings in order to improve survivor health and well-being. This will be completed through three primary aims: 1) To ascertain workflow and map community resources needed to facilitate social risk factor screening and referral for breast and prostate cancer survivors in Washington, District of Columbia. 2) To determine... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Social Determinants of Health, Breast Cancer, Prostate Cancer, Health Equity, Disparities
Register for Updates